Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance

about

Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance

Item

http://www.wikidata.org/entity/Q58423076

description

im August 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 20 August 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance

@en

Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance

@nl

type

Item

label

Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance

@en

Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance

@nl

prefLabel

Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance

@en

Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance

@nl

P1476

Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance

@en

P2093

Andrew Yang

http://www.w3.org/2001/XMLSchema#string

Bo Wook Kim

http://www.w3.org/2001/XMLSchema#string

Cassian Yee

http://www.w3.org/2001/XMLSchema#string

Chih-Ping Mao

http://www.w3.org/2001/XMLSchema#string

Eun Joo Chung

http://www.w3.org/2001/XMLSchema#string

Hyo-Jung Lee

http://www.w3.org/2001/XMLSchema#string

Hyun Cheol Bae

http://www.w3.org/2001/XMLSchema#string

Jae-Hoon Kim

http://www.w3.org/2001/XMLSchema#string

Joon-Yong Chung

http://www.w3.org/2001/XMLSchema#string

Ki-Tae Ha

http://www.w3.org/2001/XMLSchema#string

P2860

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

Hallmarks of Cancer: The Next Generation

HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing

Understanding the Warburg effect: the metabolic requirements of cell proliferation

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Mitochondrial ROS and cancer drug resistance: Implications for therapy

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

P304

4098-4114

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI96804

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

128

http://www.w3.org/2001/XMLSchema#string

P50

Hanbyoul Cho

P577

2018-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30124467

http://www.w3.org/2001/XMLSchema#string

P921

mitochondrion

P932

6118592

http://www.w3.org/2001/XMLSchema#string